408356-52-5

Basic information

• Product Name: C-(1H-INDOL-7-YL)-METHYLAMINE
• Synonyms: 1H-INDOL-7-YL-METHYLAMINE;INDOLE-7-METHYLAMINE;C-(1H-INDOL-7-YL)-METHYLAMINE;7-(Aminomethyl)indole;1H-Indole-7-MethanaMine;(1H-Indol-7-yl)methanamine
• CAS NO: 408356-52-5
• Molecular Formula: C9H10N2
• Molecular Weight: 146.19
• Product Categories: pharmacetical
• Mol File: 408356-52-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 335.599°C at 760 mmHg
• Flash Point: 183.277°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.698
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: C-(1H-INDOL-7-YL)-METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: C-(1H-INDOL-7-YL)-METHYLAMINE(408356-52-5)
• EPA Substance Registry System: C-(1H-INDOL-7-YL)-METHYLAMINE(408356-52-5)

Safety Data

• Hazardous Substances Data: 408356-52-5(Hazardous Substances Data)

Usage

General Description

C-(1H-INDOL-7-YL)-METHYLAMINE, also known as 1H-indole-7-ylmethylamine, is a chemical compound with the molecular formula C10H12N2. It is an aromatic amine derivative of indole, a heterocyclic organic compound. This chemical is commonly used in organic synthesis and pharmaceutical research, as it can serve as a precursor for the synthesis of various indole-based compounds with potential biological activity. C-(1H-INDOL-7-YL)-METHYLAMINE is a colorless to light yellow liquid at room temperature, and it has a distinct amine odor. It is important to handle this chemical with care, as it may cause skin and eye irritation, and it is also toxic if ingested or inhaled.

InChI:InChI=1/C9H10N2/c10-6-8-3-1-2-7-4-5-11-9(7)8/h1-5,11H,6,10H2

Upstream product

• 1108723-69-8 (Z)-1H-indole-7-carbaldehyde oxime 
• 1074-88-0 1H-indole-7-carbaldehyde 

Relevant articles and documents

Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity

CrtN has been identified as an attractive and druggable target for treating pigmented Staphylococcus aureus infections. More than 100 new compounds were synthesized, which target the overwhelming the defects of the CrtN inhibitor 1. Analogues 23a and 23b demonstrated a significant activity against pigmented S. aureus Newman and 13 MRSA strains (IC50 = 0.02-10.5 nM), along with lower hERG inhibition (IC50 > 30 μM, ～10-fold decrease in comparison with 1). Furthermore, 23a and 23b were confirmed to reduce the staphylococcal load in the kidney and heart in a mouse model with normal treatment deeper than pretreatment ones, comparable even with vancomycin and linezolid. Remarkably, 23a could strongly block the pigment biosynthesis of these nine multidrug-resistant MRSA strains, including excellent activity against LRSA strains and VISA strains in vivo, and all of which demonstrated that 23a has a huge potential against intractable MRSA, VISA, and LRSA issues as a therapeutic drug.

Methods and compounds for treating proliferative diseases

The compounds disclosed herein are indolocarbazoles of Formula (I), which are potent CDK4 inhibitors, and are useful in the treatment of cell proliferative disorders, including cancer. Formula (I).